Pulseless ventricular tachycardia primary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]
Overview
Overview
Implantable cardiac defibrillators are recommended in high-risk patients i.e, patients with dilated cardiomyopathy for the primary prevention of pulseless ventricular tachycardia.
Primary Prevention
Primary Prevention
- Implantable cardiac defibrillators are recommended in high-risk patients 1.e, patients with dilated cardiomyopathy for the primary prevention of pulseless ventricular tachycardia.[1]
- Implantable cardiac defibrillators have shown to significantly decrease mortality rates when compared to medical treatment for the prevention of sudden cardiac death.[2]
References
References
- ↑ Callaway CW (January 2013). “Epinephrine for cardiac arrest”. Curr. Opin. Cardiol. 28 (1): 36–42. doi:10.1097/HCO.0b013e32835b0979. PMID 23196774.
- ↑ Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautam S, Kim RJ, Kramer DB, Lambrakos LK, Nasser NH, Sorajja D (October 2018). “Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society”. Heart Rhythm. 15 (10): e253–e274. doi:10.1016/j.hrthm.2017.10.037. PMID 29097318.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH